HOME >> MEDICINE >> NEWS
Pitt transplant researchers say anti-rejection drug rapamycin may help lupus, some cancers

PITTSBURGH, Jan. 22 Rapamycin, a drug approved for use in kidney transplant patients to prevent organ rejection, could also benefit patients with lupus and other autoimmune diseases as well as patients with blood cancers, such as acute myeloid leukemia, reports a team of researchers from the University of Pittsburgh's Thomas E. Starzl Transplantation Institute and Institute of Clinical Immunology and Transfusion Medicine, Justus-Liebig University in Giessen, Germany.

Their conclusions, outlined in a paper to be published in the journal Blood and currently posted on the journal's Web site (www.bloodjournal.org), were based on two key discoveries about rapamycin's mechanisms.

First, while rapamycin suppresses immune system T cells, as many anti-rejection drugs do, the researchers found that the drug also inhibits the function and activation of dendritic cells, cells that play a much earlier role in the immune response as the first cells to identify foreign intruders. They in turn present these intruders to other immune system cells, including T cells.

Second, and perhaps more surprising to the study's authors, rapamycin disarms the trigger that allows dendritic cells to proliferate. This trigger, a potent, naturally occurring growth factor, also affects the proliferation of blood precursor and stem cells, which if allowed to grow unchecked, result in leukemia and other cancers.

"Rapamycin's effect on dendritic cells impairs immune reactivity at the earliest stages. Because dendritic cells are important for the initiation and regulation of immune response, this effect is very important. Our findings provide novel insight into the pharmacology of this agent and have significant implications for the development of new therapeutic strategies in disease processes in which dendritic cells play a crucial immunopathological role," stated Angus W. Thomson, Ph.D., D.Sc., professor of surgery and immu
'"/>

Contact: Lisa Rossi
412-647-3555
University of Pittsburgh Medical Center
22-Jan-2003


Page: 1 2

Related medicine news :

1. Success of liver transplantation may be most influenced by three risk factors
2. Alcohol relapse adversely affects 10-year liver transplant survival
3. Donor age has no affect on long-term liver transplant survival
4. Age shouldnt be a factor in kidney transplantation
5. Cornea transplants can be improved
6. Investigational transplant drug effectively preserves kidneys while avoiding toxic side effects
7. Hard choices: Pitt researcher presents findings on when to accept organ transplants
8. Biochemical marker aids prognosis in liver transplant patients
9. Single-donor islet transplantation procedure shows promise for patients with type 1 diabetes
10. Age should not be a factor in determining heart transplantation eligibility, researchers say
11. Study explores risks of obesity in children with kidney transplants

Post Your Comments:
(Date:10/30/2014)... of data from an institutional patient registry on ... control, 79 percent of tumors, for medically inoperable, ... from 2003 to 2012, according to research presented ... Thoracic Oncology. The Symposium is sponsored by the ... Society for Radiation Oncology (ASTRO), the International Association ...
(Date:10/30/2014)... WHAT: , A mathematical model developed by NIH grantees ... daily to prevent HIV infection via vaginal sex, whereas ... HIV infection via anal sex. This finding helps explain ... or PrEP, in women failed to show efficacy. Participants ... trials of Truvada and tenofovir (another antiretroviral) for HIV ...
(Date:10/30/2014)... Graphics, coding, typography and search engine optimization– ... of web design and require thorough knowledge to create ... to create a website can be as easy as ... reviews and Facebook posts all accumulate on a multiple ... evolution of how a business can develop a website," ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Five months ... Hodgkinson Street LLC announces new branding and a ... Street Mepham . After David Mepham’s promotion to name ... brand and website to include Mepham’s name and better ... malpractice and mediation firm, the decision to implement new ...
(Date:10/30/2014)... 2014 Radio listeners who indicate use ... the impact of traditional radio commercials and have overwhelmingly ... to influence a purchasing decision. , Those are some ... conducted by radio marketing company CRN International. The research ... results of respondents who indicated they have purchased or ...
Breaking Medicine News(10 mins):Health News:Sustained local control for medically inoperable, early stage lung cancer patients 2Health News:Sustained local control for medically inoperable, early stage lung cancer patients 3Health News:Model by NIH grantees explains why HIV prevention dosing differs by sex 2Health News:Facebook Websites In Thirty-Seconds 2Health News:Hodgkinson Street Mepham Rebrands 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3
(Date:10/30/2014)... 2014   ViaDerma, Inc. (OTCQB: VDRM), ... products to market, has recently released a revolutionary ... a topical liquid tetracycline-based antibiotic that uses a ... oral medication active ingredients into topical drugs. The ... antibiotic to help prevent skin infection in minor ...
(Date:10/30/2014)... CVS Health (NYSE: CVS ) announced ... leading regional health systems to enhance access to high-quality, affordable ... Baptist Health System in Alabama ; Community ... Pennsylvania , Northwest Medical Center, including Oro ... Healthcare in Tennessee ; and Premier Health ...
(Date:10/30/2014)... Kingdom , Oct. 30, 2014 Molecular ... CBRX ) and Maryland ... developers with improved efficiency during clinical development that will ... next week. This partnership extends ... platform, which it launched earlier this month. The company ...
Breaking Medicine Technology:ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 2CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 4Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3
Cached News: